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Coenzyme Q10
An Independent Predictor of Mortality in Chronic Heart Failure
Sarah L. Molyneux, PHD,* Christopher M. Florkowski, MD,* Peter M. George, MB, BS,*
Anna P. Pilbrow, PHD,† Christopher M. Frampton, PHD,† Michael Lever, PHD,*
A. Mark Richards, MD, PHD†
Christchurch, New Zealand
Objectives The aim of this study was to investigate the relationship between plasma coenzyme Q10 (CoQ10) and survival in
patients with chronic heart failure (CHF).
Background Patients with CHF have low plasma concentrations of CoQ10, an essential cofactor for mitochondrial electron
transport and myocardial energy supply. Additionally, low plasma total cholesterol (TC) concentrations have been
associated with higher mortality in heart failure. Plasma CoQ10 is closely associated with low-density lipoprotein
cholesterol (LDL-C), which might contribute to this association. Therefore we tested the hypothesis that plasma
CoQ10 is a predictor of total mortality in CHF and could explain this association.
Methods Plasma samples from 236 patients admitted to the hospital with CHF, with a median (range) duration of
follow-up of 2.69 (0.12 to 5.75) years, were assayed for LDL-C, TC, and total CoQ10.
Results Median age at admission was 77 years. Median (range) CoQ10 concentration was 0.68 (0.18 to 1.75) mol/l.
The optimal CoQ10 concentration for prediction of mortality (established with receiver-operator characteristic
[ROC] curves) was 0.73 mol/l. Multivariable analysis allowing for effects of standard predictors of survival—
including age at admission, gender, previous myocardial infarction, N-terminal peptide of B-type natriuretic pep-
tide, and estimated glomerular filtration rate (modification of diet in renal disease)—indicated CoQ10 was an
independent predictor of survival, whether dichotomized at the ROC curve cut-point (hazard ratio [HR]: 2.0; 95%
confidence interval [CI]: 1.2 to 3.3) or the median (HR: 1.6; 95% CI: 1.0 to 2.6).
Conclusions Plasma CoQ10 concentration was an independent predictor of mortality in this cohort. The CoQ10 deficiency
might be detrimental to the long-term prognosis of CHF, and there is a rationale for controlled intervention stud-
ies with CoQ10. (J Am Coll Cardiol 2008;52:1435–41) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.044k
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hoenzyme Q 10 (CoQ 10) is a fat-soluble quinone found in
ll cells, essential for adenosine triphosphate generation via
itochondrial oxidative phosphorylation (1). Its depletion
ight exacerbate chronic heart failure (CHF) (2,3).
It has been demonstrated that total cholesterol (TC) is
elated to survival in CHF (4–7). Rauchhaus et al. (5)
eported that lower serum TC was independently associated
ith total mortality in a CHF cohort independent of
tiology, age, left ventricular ejection fraction, and exercise
apacity. The mechanisms postulated were that cholesterol
ight limit lipopolysaccharide-induced production of cyto-
rom the *Clinical Biochemistry Unit, Canterbury Health Laboratories,
hristchurch, New Zealand; and †The Christchurch Cardioendocrine Research
roup, Department of Medicine, University of Otago (Christchurch), Christchurch,
ew Zealand. This study and the salary for Dr. Molyneux were funded by the
ational Heart Foundation of New Zealand.i
Manuscript received March 3, 2008; revised manuscript received July 14, 2008,
ccepted July 21, 2008.ines, and thus high levels of cholesterol might confer a
urvival advantage (5). They also postulated that high
holesterol might provide “greater metabolic reserve” to deal
ith the CHF syndrome. The authors did not, however,
efer to CoQ 10, which is known to correlate with TC
oncentration (8) and which might contribute to the worse
utcomes seen in CHF patients with low cholesterol.
yocardial deficiency of CoQ 10 has been demonstrated in
eart failure, and the severity of the deficiency correlated
ith severity of symptoms. Patients in New York Heart
ssociation (NYHA) functional class IV have significantly
ower CoQ 10 in endomyocardial biopsy samples than those
n NYHA functional class I (3).
Although beneficial effects of CoQ 10 supplementation in
HF have been reported (9–23) and intervention studies
uch as Q-SYMBIO have been initiated (24), CoQ 10 levels
ave not been previously related to outcomes of heart failuren observational studies. Therefore, we tested the hypothesis
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CoQ10 and Heart Failure October 28, 2008:1435–41that CoQ 10 is associated with
cholesterol and predicts mortality
in patients with CHF.
Methods
This study was part of an ongo-
ing cohort study of biomarkers in
heart failure, with data collected
systematically and prospectively.
The CoQ 10 hypothesis was gen-
erated retrospectively.
Patients. Patients able to give
informed consent were recruited
during admission to Christchurch
Hospital with symptomatic CHF
satisfying Framingham (25) (2
major and 2 minor criteria present
concurrently) and European Soci-
ety of Cardiology (26) criteria, be-
tween July 2000 and December
2004. Plasma N-terminal peptide
f B-type natriuretic peptide (NT-proBNP) was required to
e over 50 pmol/l. Exclusion criteria included active myo-
arditis/pericarditis, life expectancy due to noncardiovascu-
ar disease of 24 months, severe hepatic or pulmonary
isease (forced expiratory volume 1 l), renal impairment
plasma creatinine 250 mol/l), transient heart failure
rom myocardial infarction (MI) treated with acute revas-
ularization and a subsequent ejection fraction during the
ndex hospital admission of 40%, severe valvular disease
eing considered for surgery, severe aortic stenosis (valve
rea 1 cm2), heart failure secondary to mitral stenosis,
nder consideration for cardiac transplantation, and age
18 years. A total of 3,576 patients were screened, yielding
98 eligible patients, of which 236 qualifying patients were
nrolled. Eighty-four patients were excluded from the
onsented population on the basis of the exclusion
riteria, primarily due to a reduction in NT-proBNP
etween consent (during hospital stay) and blood sam-
ling. Qualifying patients visited within 28 days of the
ndex hospital admission for collection of blood plasma sam-
les, which were stored at 80°C.
At admission, all patients were severely symptomatic with
eart failure. However, at the time of blood collection
median of 48 days after the index hospital admission), 65%
ere in NYHA functional class II. The median ejection
raction was 37%.
This study received ethical approval from the Canterbury
thics Committee, and written informed consent was
btained from all participants.
ollow-up. Patients were followed-up for a median of 2.69
range 0.12 to 5.75) years. Patients were followed up at a
inimum of 3 monthly intervals to document medications,
Abbreviations
and Acronyms
CHF  chronic heart failure
CI  confidence interval
CoQ10  coenzyme Q10
GFR  glomerular filtration
rate
LDL-C  low-density
lipoprotein cholesterol
MDRD  modification of
diet in renal disease
MI  myocardial infarction
NT-proBNP  N-terminal
peptide of B-type
natriuretic peptide
NYHA  New York Heart
Association
ROC  receiver-operator
characteristic
TC  total cholesteroldverse events, readmissions to hospital, and death. No (atients were lost to follow-up. The primary end point of
his study was all-cause mortality.
easurement of analytes. Plasma total CoQ 10 was mea-
ured with high-performance liquid chromatography with
lectrochemical detection, similarly to Tang et al. (2001)
27). The within- and between-run coefficients of variation
or the CoQ 10 assay are approximately 3.3%. The TC was
etermined by an enzymatic colorimetric method (Aeroset
nalyser Model LN, Abbott Laboratories, Chicago, Illi-
ois), with a coefficient of variation of 1.6%. Direct low-
ensity lipoprotein cholesterol (LDL-C) was measured with
oche Diagnostics reagents (Indianapolis, Indiana), with a
oefficient of variation of 1.2%. The NT-proBNP was
easured by immunoassay, with a coefficient of variation of
3% (28). Glomerular filtration rate (GFR) was estimated
y the modification of diet in renal disease (MDRD) study
quation (29).
tatistical analysis. Statistics were computed with SPSS
ersion 11.5 (SPSS, Inc., Chicago, Illinois); p  0.05 was
onsidered significant. Due to skewed distributions, non-
arametric statistics were used, and values are expressed as
edians and ranges or percentages, as indicated. Reported
orrelations are Spearman rank correlations (R). To com-
are different predictive values at a particular time point,
reas under the curve for sensitivity and specificity were
onstructed (receiver-operator characteristic [ROC] curve)
MedCalc 1993 to 2005, MedCalc Software, Mariakerke,
elgium). The best cutoff value for survival status at a given
ime point was defined as that point closest to the (0,1)
oint (the minimum Euclidean distance). Cox proportional
azards analyses were used to assess prognostic associations.
base model containing standard predictors of survival was
onstructed, which included age, gender, history of previous
I, glomerular filtration rate, and NT-proBNP, with
dditional factors added on to the base model as described.
he hazard ratio (HR) with 95% confidence interval (CI)
nd p values by the likelihood ratio test are presented.
aplan-Meier cumulative survival plots from date of admis-
ion were constructed with dichotomous data obtained with
he cut-point from the ROC curve. Significance values for
aplan-Meier curves are the log-rank comparisons. Differ-
nces in demographic variables for patients surviving more
han and 1 year were compared with the Mann-Whitney
ank sum test or chi-square test (Pearson chi-square 2-sided
symptotic significance).
esults
amples from 236 patients were analyzed. The median
range) follow-up time was 2.7 (0.1 to 5.8) years. A total of
6 events (deaths) occurred. Maximum storage time for
amples was 5.4 years. The patient demographic data of the
omplete cohort and the survivors and nonsurvivors at 1 year
re shown in Table 1.
There was a significant correlation between CoQ 10 and TC
R 0.663, p 0.001) and LDL-C (R 0.573, p 0.001)
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(MDRD)  estimated glomerular filtration rate calculated with the modification of diet in renal disease
f -terminal peptide of B-type natriuretic peptide; TC  total cholesterol.
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October 28, 2008:1435–41 CoQ10 and Heart Failurend inversely between CoQ 10 and NT-proBNP (R 
0.258, p  0.001). There was also a weaker but significant
egative correlation between TC and NT-proBNP (R 
0.190, p  0.004).
The ROC curves were constructed for putative predictors
f survival. Significant discrimination was observed for
oQ 10 (Fig. 1), the ratios of CoQ 10 to TC and CoQ 10 to
DL-C, and also NT-proBNP and GFR (MDRD). A
omparison of patient demographic data for patients with
oQ 10 values higher and lower than the ROC curve
ptimal cut-point (0.73 mol/l) (Fig. 1) is shown in Table
. Neither TC nor LDL-C by themselves significantly
iffered from zero discrimination (diagonal on ROC curve),
nd hence no cutoff value for predicting survival could be
etermined. The ROC curve cut-points were also used in a
ultivariate analysis as outlined in the following text.
Kaplan-Meier curves for CoQ 10 (Fig. 2A), the CoQ 10
o TC ratio, and the CoQ 10 to LDL-C ratio—
ichotomized for either the ROC curve cut-point or the
edian (data not shown)—showed significant differences
n survival (p  0.01), with lower CoQ 10 and CoQ 10 to
ipid ratios predicting poorer survival. Additionally, a
linical and Biochemical Characteristics of All Patientst Index Hosp tal Admission and of Survivors and No survivors at 12 M
Table 1 Clinical and Biochemical Characteristics of All Patientsat Index Hospital Admission and of Survivors and Nonsurv
Variable All Patients (n  236)
Age at admission (yrs) 77 (32–89)
Male gender (%) 63
Weight (kg) 75 (45–159)
Height (cm) 168 (145–193)
BMI (kg/m2) 26 (18–43)
GFR (MDRD) (ml/min/1.73 m2) 60 (17–123)
NT-proBNP (pmol/l) 238 (15–1540)
CoQ10 (mol/l) 0.68 (0.18–1.75)
TC (mmol/l) 4.78 (2.10–11.43)
LDL-C (mmol/l) 2.52 (0.68–7.31)
CoQ10/TC ratio (mmol/mol) 0.14 (0.05–0.38)
CoQ10/LDL-C ratio (mmol/mol) 0.26 (0.09–0.84)
Previous MI (%) 48
Diabetes (%) 21
Renal disease (%) 28
Smoking (%)
Current 4
Past 55
Never 41
Medications (%)
ACE inhibitor at admission 53
ACE inhibitor at discharge 82
Beta-blocker at admission 39
Beta-blocker at discharge 63
Statin at admission 33
Statin at discharge 45
alues are expressed as median (range) or percentage. *p values are for comparison between su
etermined with the chi-square test.
ACE  angiotensin-converting enzyme; BMI  body mass index; CoQ10  coenzyme Q10; GRF
ormula; LDL-C  low-density lipoprotein cholesterol; MI  myocardial infarction; NT-proBNP  Naplan-Meier curve for a 4-way split between CoQ 101 - Specificity
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Figure 1 Receiver-Operator Characteristic Curve for CoQ10
The receiver-operator characteristic curve for plasma coenzyme Q10 (CoQ10)
(red line) as a predictor of total mortality, showing the optimal cut-point of
0.73 mol/l. The green line represents the zero discrimination line.onths
ivors at 12 Months
12 Months
Nonsurvivors (n  29) Survivors (n  205) p Value*
79 (61–86) 77 (32–89) 0.05†
62 63 0.89‡
69 (45–96) 75 (47–159) 0.12†
168 (150–183) 168 (145–193) 0.98†
25 (18–35) 26 (19–43) 0.07†
59 (23–120) 60 (17–123) 0.37†
257 (71–1094) 234 (15–1540) 0.42†
0.56 (0.18–1.29) 0.69 (0.20–1.75) 0.04†
4.46 (2.88–6.26) 4.90 (2.10–11.43) 0.08†
2.47 (1.38–3.76) 2.62 (0.68–7.31) 0.35†
0.12 (0.05–0.23) 0.14 (0.05–0.38) 0.12†
0.24 (0.09–0.41) 0.27 (0.09–0.84) 0.14†
59 46 0.20‡
28 20 0.35‡
28 27 0.98‡
7 4
52 55 0.73‡
38 41
55 53 0.80‡
72 83 0.15‡
41 39 0.81‡
62 63 0.89‡
41 31 0.27‡
45 44 0.97‡
rvivors and nonsurvivors at each time point. †As determined with the Mann-Whitney rank sum test. ‡As
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CoQ10 and Heart Failure October 28, 2008:1435–41nd NT-proBNP showed significantly better survival
elated to high CoQ 10 combined with low NT-proBNP
evels compared with low CoQ 10 and high NT-proBNP
evels (Fig. 2B). There is significantly better survival asso-
iated with high CoQ 10 plus high NT-proBNP than there
s with low CoQ 10 together with high NT-proBNP. And
here is significantly better survival associated with low CoQ 10
nd low NT-proBNP than there is with low CoQ 10 and high
T-proBNP (Fig. 2B).
Multivariable analysis allowing for effects of standard
redictors of survival, including age at admission, gender,
revious MI, estimated GFR (MDRD), and NT-
roBNP, showed that CoQ 10 was an independent pre-
ictor of survival, whether dichotomized at the ROC
urve cut-point (HR: 1.99; 95% CI: 1.21 to 3.30, p 
.007) or the median (0.68 mol/l) (HR: 1.62; 95% CI:
.01 to 2.59, p  0.05) (Table 3). Total cholesterol was not
 significant predictor of survival either added to the model
s a continuous variable or dichotomized for the ROC curve
ut-point of 5.2 mmol/l determined by Rauchhaus et al. (5)
Clinical and Biochemical Characteristics of PatiAbove and Bel w the Mortality ROC Curve Cut-P
Table 2 Clinical and Biochemical CharacterAbove and Below the Mortality ROC
Variable
CoQ10 Below
Curve Cut-P
(CoQ10 0.18–0.73
(n  137
Age at admission (yrs) 78
Male gender (%) 64
Died (%) 39
Weight (kg) 75
Height (cm) 168
BMI (kg/m2) 26
GFR (MDRD) (ml/min/1.73 m2) 59
NT-proBNP (pmol/l) 258
CoQ10 (mol/l) 0.53
TC (mmol/l) 4.30
LDL-C (mmol/l) 2.27
CoQ10/TC ratio (mmol/mol) 0.12
CoQ10/LDL-C ratio (mmol/mol) 0.23
Previous MI (%) 53
Diabetes (%) 23
Renal disease (%) 33
Smoking (%)
Current 3
Past 58
Never 39
Medications (%)
ACE inhibitor at admission 54
ACE inhibitor at discharge 82
Beta-blocker at admission 44
Beta-blocker at discharge 71
Statin at admission 38
Statin at discharge 55
Values are expressed as median (range) or percentage. *As determine
test.
ROC  receiver-operator characteristic; other abbreviations as in TaTable 3). CThe ratio of CoQ 10 to TC was a significant predictor of
urvival when added to the base model as a continuous
ariable (HR [for a 10-U change in the CoQ 10 to TC
atio]: 2.00; 95% CI: 1.03 to 3.85, p  0.04) as well as when
ichotomized for the median (median  0.14 mmol/mol)
HR: 2.01; 95% CI: 1.23 to 3.31, p  0.006). Similarly, the
atio of CoQ 10 to LDL-C was close to significant predictor
hen added to the base model as a continuous variable (HR:
2.50; 95% CI: 0.97 to 100.00, p  0.05) as well as
ichotomized for the median (median  0.26 mmol/mol)
HR: 1.61; 95% CI: 1.00 to 2.59, p  0.05). Neither
DL-C nor TC dichotomized at the median or statins at
ischarge were independent predictors of survival when
dded to the base model, either independently or together.
iscussion
e have found an independent association between lower
oQ 10 and increased risk of mortality in CHF. The
trength of association between CoQ10 and mortality (HR:
.99) was greater than that observed for NT-proBNP. The
With CoQ10 Concentrations(0.73 mol/l)
of Patients With CoQ10 Concentrations
ve Cut-Point (0.73 mol/l)
/l)
CoQ10 Above ROC
Curve Cut-Point
(CoQ10 0.73–1.75 mol/l)
(n  98) p Value
76 0.34*
63 0.90†
22 0.007†
76 0.65*
169 0.88*
27 0.36*
61 0.04*
194 0.004*
0.92 0.001*
5.45 0.001*
3.04 0.001*
0.17 0.001*
0.31 0.001*
40 0.04†
17 0.26†
20 0.04†
6
50 0.28†
44
52 0.77†
83 0.86†
33 0.08†
53 0.005†
26 0.05†
31 0.001†
he Mann-Whitney rank sum test. †As determined with the chi-squareentsoint
istics
Cur
ROC
oint
mol
)
d with toQ 10 predicted outcome independently of NT-proBNP,
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October 28, 2008:1435–41 CoQ10 and Heart Failureuggesting that its longer-term contribution to function
ight be important regardless of the initial severity of the
eart failure. The predictive power of CoQ 10 was signifi-
ant when included in the model dichotomized according to
ither the median value or ROC curve optimal cut-point for
urvival. It is recognized that CoQ 10 deficiency occurs in
HF (3) and that this might compromise mitochondrial
Figure 2 Survival Related to CoQ10 Concentration
and to CoQ10 and NT-proBNP 4-Way Split
(A) Survival related to the best predictive value of mortality for coenzyme Q10
(CoQ10) as determined from the receiver-operator characteristic (ROC) curve
(0.73 mol/l), showing values above (green) and below (blue) this cut-point.
Log-rank p  0.001 for the difference between groups. (B) Kaplan-Meier sur-
vival curve for patients with above- and below-median CoQ10 in combination
with above- and below-median N-terminal peptide of B-type natriuretic peptide
(NT-proBNP). Differences in survival among patient groups are indicated, except
where nonsignificant. Medians: CoQ10  0.68 mol/l; NT-proBNP  238
pmol/l. Values below graphs indicate the number of subjects remaining in the
study at each time point.unction. It is therefore plausible that CoQ 10 deficiency
5ight be an important pathogenic mechanism associated
ith worse outcomes in CHF. Follow-up samples to deter-
ine whether CoQ 10 levels remain persistently depleted
ould provide interesting further information on the role of
oQ 10 in heart failure.
We were unable to confirm an independent association of
lasma cholesterol with total mortality, as has been previ-
usly reported (4–7). This might be due to differences in the
study populations. Rauchhaus et al. (5) enrolled patients
ith CHF from a CHF and cardiomyopathy clinic with
uration of CHF between 6 months and 20 years. The
ajority were in NYHA functional class III (5). Our cohort
as less symptomatic at the time of sampling and had
arious etiologies. Our group was older (median age 77
ears in our study vs. mean ages of 63.0 and 62.1 years in the
erivation and validation studies of Rauchhaus et al. [5],
espectively) and was followed-up for a longer duration. Our
atients were recruited during admission to the hospital
ith symptomatic CHF, with the majority being discharged
n NYHA functional class II. These differences might
ccount for the failure to confirm plasma cholesterol as a
redictor of mortality.
It has also been shown that the myocardium in patients
ith heart failure is deficient in CoQ 10 (3). Because plasma
otal CoQ 10 concentrations correlate with TC, the ratio of
oQ 10 to TC and/or LDL-C might be a better marker of
oQ 10 status and hence survival. However, our results with
he CoQ 10 concentrations adjusted for lipids (TC or
DL-C) are similar to those with unadjusted CoQ 10
oncentrations, suggesting that the use of adjusted values
ffers no advantage.
The low number of events in our study (n  76) is a
imitation, and it is possible that some of the borderline
ssociations found were affected by this. The low number of
vents also limited the number of baseline variables that
ould be added to the multivariable models, and, therefore,
e have concentrated our analyses on the most established
nd accepted predictors of survival.
The association of CoQ 10 and survival brings into
uestion the role of statins in CHF. The role of statins in
ox Proportional Hazards Model Analysisf Fact rs Predictive of Mortality for the Cohort
Table 3 Cox Proportional Hazards Model Analysisof Factors Predictive of Mortality for the Cohort
Variable Coefficient HR 95% CI for HR p Value
Age at admission (yrs) 0.059 1.06 1.02–1.10 0.001
Gender (male) 0.243 1.28 0.78–2.09 0.34
Previous MI 0.244 1.28 0.81–2.02 0.30
GFR (MDRD) (ml/min/1.73 m2) 0.015 0.99 0.97–1.00 0.03
NT-proBNP* 0.597 1.82 1.11–2.98 0.02
CoQ10† 0.690 1.99 1.21–3.30 0.007
CoQ10* 0.481 1.62 1.01–2.59 0.05
TC (mmol/l) 0.027 1.03 0.83–1.27 0.81
TC‡ 0.004 1.00 0.60–1.67 0.99
Dichotomized for median split. †Dichotomized for ROC curve optimal cut-point. ‡Dichotomized at
.2 mmol/l, the ROC curve cut-point determined by Rauchhaus et al. (5).
CI  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 2.
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CoQ10 and Heart Failure October 28, 2008:1435–41HF is controversial (30); however, statin use has been
ssociated with lower risk of death in patients with CHF
7,31). CoQ 10 and cholesterol are both products of the
evalonate biosynthetic pathway, and statin therapy also
owers plasma total CoQ 10 (32). If statins do confer benefit
n CHF patients, it might be through mechanisms other
han cholesterol reduction, so called pleiotropic effects. In 1
mall study (33), CoQ 10 reduction on statin therapy was
ssociated with an improvement in endothelial function in
HF patients, suggesting that it might be a marker of
leiotropism. Larger and more long-term interventional
tudies with statins in CHF are required to assess the effect
n clinical outcomes.
In our present study, patients with higher CoQ 10
above the ROC curve cut-point) were less likely to be
eceiving statins (or beta-blocker drugs); however, statin
herapy at discharge from the index admission was not an
ndependent predictor of survival, and CoQ 10 remained
n independent predictor of mortality in a multivariable
odel that included statin treatment. The CORONA
Controlled Rosuvastatin Multinational Trial in Heart
ailure) investigators failed to show a reduction in major
ascular events in older patients with systolic heart failure
34). It could be postulated that this was due to a
eduction in CoQ 10 that offset any other beneficial effect
f statin and warrants further investigation with a larger
ample size than the current study.
Several clinical trials (10–17,19–22) have suggested ben-
fits from CoQ 10 supplementation in CHF. Two meta-
nalyses of CoQ 10 supplementation in CHF have been
onducted. Soja and Mortensen (9) used 8 double-blind
lacebo-controlled studies (10–17) and reported a signifi-
ant improvement in stroke volume, ejection fraction, car-
iac output, cardiac index, and end-diastolic volume index,
s a consequence of CoQ 10 supplementation. Changes in
ystolic time intervals and total work capacity were not
tatistically significant (9). More recently, Sander et al. (18)
sed 11 studies—10 that evaluated ejection fraction (10,12–
4,17,19–22), and 2 that evaluated cardiac output (16,23)—
ith CoQ 10 doses ranging from 60 to 200 mg/day and
reatment periods ranging from 1 to 6 months. A 3.7% net
mprovement in the ejection fraction was found, and cardiac
utput was increased an average of 0.28 l/min (18). Recently
n international multicenter intervention study, Q-SYMBIO,
as been initiated (24). This is a randomized, double-blind,
ulticenter trial with focus on symptoms, biomarker status
B-type natriuretic peptide), and long-term outcomes (24).
No previous studies, however, have formally studied the
elationship between CoQ 10 and outcomes in CHF in a
ongitudinal observational study such as ours. Our findings
n a clearly defined, prospectively studied group that CoQ 10
epletion is associated with worse outcomes in CHF give
urther support to the rationale of the intervention studies
hat have already been initiated.
1onclusions
lasma CoQ 10 is an independent predictor of mortality in
HF. CoQ 10 deficiency might be implicated in the long-
erm prognosis of CHF, and there is a rationale for further
ontrolled intervention studies of CoQ 10 supplementation.
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